LAMP2 and primary biliary cholangitis: In our retrospective cohort study, there were 61% patients with PBC were in the early stage, and 39% in the late stage, we then separately evaluated the decrease of LAMP-2 level to identify UDCA-responder at 3 months of treatment for patients based on their disease stages.